{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:41:21Z","timestamp":1792636881940,"version":"4.5.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Enfortumab vedotin (EV) has been demonstrated to have a significant response rate in early phase trials and is known for its tolerable side-effect profile. Emerging case reports have raised awareness of cutaneous toxicities, which may be a potentially fatal complication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the potential relevance between EV and cutaneous toxicities reports through data mining of the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from January 1, 2019, to November 4, 2021, in the FAERS database were retrieved. Information component (IC) and reporting odds ratio (ROR) were used to evaluate the association between EV and cutaneous toxicities events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>EV was significantly associated with cutaneous toxicities in the database compared with both all other drugs (ROR 12.90 [10.62\u201315.66], IC 2.76 [2.52\u20133.01], middle signal) and platinum-based therapy (ROR 15.11 [12.43\u201318.37], IC 2.91 [2.66\u20133.15], middle signal) in the FAERS database. A significant association was detected between EV and all the cutaneous adverse effects (AEs) except erythema, palmar\u2013plantar erythrodysesthesia syndrome, and dermatitis allergic. Both Stevens\u2013Johnson syndrome and toxic epidermal necrolysis occurred 15 times as frequently for EV compared with all other drugs (ROR = 15.20; ROR = 15.52), while Stevens\u2013Johnson syndrome occurred 18 times and toxic epidermal necrolysis occurred 7 times as frequently for EV compared with platinum-based therapy in the database (ROR = 18.74; ROR = 7.80). All groups that limited the gender and age showed a significant association between EV and cutaneous toxicities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A significant signal was detected between EV use and cutaneous toxicities. It is worth noting that Stevens\u2013Johnson syndrome and toxic epidermal necrolysis were significantly associated with EV use.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.801199","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T04:53:49Z","timestamp":1642568029000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.3389","volume":"11","author":[{"given":"Hui","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoling","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/1756287220980192","article-title":"Enfortumab Vedotin in Urothelial Cancer","volume":"12","author":"Alt","year":"2020","journal-title":"Ther Adv Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41571-021-00523-y","article-title":"Sacituzumab Govitecan is Safe and Effective","volume":"18","author":"Sidaway","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2020.56.5.3127027","article-title":"Enfortumab Vedotin to Treat Urothelial Carcinoma","volume":"56","author":"Hanna","year":"2020","journal-title":"Drugs Today (Barc)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4\u2013Positive Solid Tumors, Including Metastatic Urothelial Carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death\/Programmed Death Ligand 1 Therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1865910","article-title":"Enfortumab Vedotin -Next Game- Changer in Urothelial Cancer","volume":"21","author":"Maas","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz249","article-title":"EV-103: Initial Results of Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma","volume":"30","author":"Hoimes","year":"2019","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2069","article-title":"798tip Study EV-302: A 3-Arm, Open-Label, Randomized Phase III Study of Enfortumab Vedotin Plus Pembrolizumab and\/or Chemotherapy, Versus Chemotherapy Alone, in Untreated Locally Advanced or Metastatic Urothelial Cancer","volume":"31","author":"van der Heijden","year":"2020","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e8102","DOI":"10.7759\/cureus.8102","article-title":"Flexural Exanthema From Enfortumab Vedotin","volume":"12","author":"Keerty","year":"2020","journal-title":"Cureus"},{"key":"B13","doi-asserted-by":"publisher","first-page":"13030\/qt4j44w7w6","DOI":"10.5070\/D3252042890","article-title":"Cutaneous Toxicity Associated With Enfortumab Vedotin Treatment of Metastatic Urothelial Carcinoma","volume":"25","author":"Wu","year":"2019","journal-title":"Dermatol Online J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15577","article-title":"Severe Eczematoid and Lichenoid Eruption With Full-Thickness Epidermal Necrosis Developing From Metastatic Urothelial Cancer Treated With Enfortumab Vedotin","volume":"47","author":"Sasaki","year":"2020","journal-title":"J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.10.020","article-title":"A Rare Presentation of Enfortumab Vedotin-Induced Toxic Epidermal Necrolysis","volume":"7","author":"Francis","year":"2020","journal-title":"JAAD Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.621591","article-title":"Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction","volume":"11","author":"Viscuse","year":"2021","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jdcr.2021.05.020","article-title":"Cutaneous Reactions With Enfortumab Vedotin: A Case Series and Review of the Literature","volume":"14","author":"Dobry","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.594043","article-title":"Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database","volume":"8","author":"Meng","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.640264","article-title":"Assessment of the Safety Signal for the Abuse Potential of Pregabalin and Gabapentin Using the FAERS Database and Big Data Search Analytics","volume":"12","author":"Papazisis","year":"2021","journal-title":"Front Psychiatry"},{"key":"B21","volume-title":"Mann\\\"s Pharmacovigilance || History of Pharmacovigilance","author":"Andrews","year":"2014"},{"key":"B22","first-page":"1","volume-title":"European Medicine Agency Guidelines","year":"2006"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.7967","article-title":"Commonality of Drug-Associated Adverse Events Detected by 4 Commonly Used Data Mining Algorithms","volume":"11","author":"Sakaeda","year":"2014","journal-title":"Int J Med Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A Comparison of Measures of Disproportionality for Signal Detection in Spontaneous Reporting Systems for Adverse Drug Reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742","article-title":"Quantitative Signal Detection Using Spontaneous ADR Reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B26","unstructured":"BateA\n          The Use of Bayesian Confidence Propagation Neural Network in Pharmacovigilance [Internet] [PhD Dissertation]2003"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab Vedotin After PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma (EV\u2212201): A Multicentre, Single-Arm, Phase 2 Trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.05.013","article-title":"New and Topics: Enfortumab Vedotin Mechanisms of Response and Resistance in Urothelial Cancer - What do We Understand So Far","volume":"39","author":"Hoffman-Censits","year":"2021","journal-title":"Urol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.119","article-title":"Nectin-4 Mutations Causing Ectodermal Dysplasia With Syndactyly Perturb the Rac1 Pathway and the Kinetics of Adherens Junction Formation","volume":"134","author":"Fortugno","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.099572","article-title":"The Role of Nectins in Different Types of Cellecell Adhesion","volume":"125","author":"Rikitake","year":"2012","journal-title":"J Cell Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1803","article-title":"U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma","volume":"18","author":"de Claro","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2959","article-title":"EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer","volume":"33","author":"Yardley","year":"2015","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and Activity of the Anti-CD79B Antibody\u2013Drug Conjugate Polatuzumab Vedotin in Relapsed or Refractory B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia: A Phase 1 Study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.801199\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T04:53:52Z","timestamp":1642568032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.801199\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":33,"alternative-id":["10.3389\/fonc.2021.801199"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.801199","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]},"article-number":"801199"}}